TY  - JOUR
AB  - This comprehensive review written by experts in their field gives an 
      overview on the current status of incorporating positron emission 
      tomography (PET) into radiation treatment planning. Moreover, it 
      highlights ongoing studies for treatment individualisation and 
      per-treatment tumour response monitoring for various primary tumours. 
      Novel tracers and image analysis methods are discussed. The authors 
      believe this contribution to be of crucial value for experts in the 
      field as well as for policy makers deciding on the reimbursement of this
       powerful imaging modality.
AU  - Lapa, C.*
AU  - Nestle, U.*
AU  - Albert, N.L.*
AU  - Baues, C.*
AU  - Beer, A.*
AU  - Buck, A.*
AU  - Budach, V.*
AU  - Buetof, R.*
AU  - Combs, S.E.
AU  - Derlin, T.*
AU  - Eiber, M.*
AU  - Fendler, W.P.*
AU  - Furth, C.*
AU  - Gani, C.*
AU  - Gkika, E.*
AU  - Grosu, A.*
AU  - Henkenberens, C.*
AU  - Ilhan, H.*
AU  - Loeck, S.*
AU  - Marnitz-Schulze, S.*
AU  - Miederer, M.*
AU  - Mix, M.*
AU  - Nicolay, N.H.*
AU  - Niyazi, M.*
AU  - Poettgen, C.*
AU  - Rödel, C.M.*
AU  - Schatka, I.*
AU  - Schwarzenboeck, S.M.*
AU  - Todica, A.S.*
AU  - Weber, W.*
AU  - Wegen, S.*
AU  - Wiegel, T.*
AU  - Zamboglou, C.*
AU  - Zips, D.*
AU  - Zoephel, K.*
AU  - Zschaeck, S.*
AU  - Thorwarth, D*
AU  - Troost, E.G.C.*
C1  - 62723
C2  - 51025
CY  - Rudigerstr 14, D-70469 Stuttgart, Germany
SP  - 326-343
TI  - Value of PET imaging for radiation therapy *.
JO  - Nuklearmedizin
VL  - 60
IS  - 5
PB  - Georg Thieme Verlag Kg
PY  - 2021
SN  - 0029-5566
ER  - 

TY  - JOUR
AB  - Radiosynoviorthesis (RSO) with the ?-particle-emitting nuclide yttrium-90 is an established concept for the treatment of persistent synovitis of the knee joint. The aim of this study was to investigate the biological radiation effect on the basis of a characteristic radiation parameter. Patients, methods: After RSO procedures with yttrium-90 citrate colloid and subsequent immobilisation of the knee, blood specimens of 10 patients were collected immediately before RSO and 11 to 13 days after the intervention. The yield of dicentric chromosomes in the lymphocytes was determined exclusively in metaphases of the first cell cycle in vitro. In addition, activity leakage was measured by wholebody bremsstrahlung-scintigraphy. Results: No statistically significant increase in the number of dicentric chromosomes (26 before treatment and 34 after treatment) in 20 192 cells analyzed from the 20 blood samples could be found as a result of RSO. However, the analysis of at least 1000 cells per blood sample demonstrates a tendency for a biological radiation effect in the blood of patients on the basis of this characteristic radiation parameter. Two of the 10 RSO patients had undergone a second RSO using yttrium- 90 citrate, whereby one patient displayed activity transport out of the knee joint, amounting to 6 MBq. Only for him a radiation effect (about 130 mGy per single RSO) could be calculated by biological dosimetry. Conclusion: Since in general, based on the analysis of dicentric chromosomes in at least 1000 lymphocytes per individual, detection limits for groups of persons after long-term exposures to low-LET radiation of 50-100 mGy are possible, we assume that RSO with yttrium-90 should be associated with a low whole-body radiation exposure.
AU  - Voth, M.*
AU  - Klett, R.*
AU  - Lengsfeld, P.*
AU  - Stephan, G.*
AU  - Schmid, E.
C1  - 5711
C2  - 24365
SP  - 223-228
TI  - Biological dosimetry after yttrium-90 citrate colloid radiosynoviorthesis.
JO  - Nuklearmedizin
VL  - 45
PY  - 2006
SN  - 0029-5566
ER  - 

TY  - JOUR
AB  - The low tumor-to-background ratio obtained after administration of radiolabeled whole monoclonal antibodies (MAbs) is one of the major problems in immunoscintigraphy and -therapy. To reduce the blood pool label caused by the circulation of radiolabeled MAb we have investigated the advantage of injecting an anti-antibody after administration of a tumor-specific MAb in nude mice bearing human mammary carcinoma xenografts. The MAb MA 10-11 of rat origin, used in these studies, had shown a high affinity to human mammary carcinoma tissue on frozen sections and low cross-reactivity with various normal human tissues. 24 h after injection of 1.5 MBq 131I-labeled MAb containing 10 μg IgG(2a) one group of mice received an additional injection of 100 μg anti-rat antibody. Blood taken 2 min after the second antibody injection showed nearly the whole activity bound to antibody aggregates, that cleared very rapidly from the circulation and accumulated in liver and spleen. The transitory high liver activity decreased within several hours because of rapid deiodination of the antibody-complex in this organ. The release of radioactivity from the spleen, however, was found to be much slower. The rapid excretion of the radioactivity from the blood pool combined with a nearly constant tumor activity allowed early tumor detection with tumor-to-blood ratios of 250:1 at 48 h after anti-antibody injection compared to 1.1:1 obtained for the control animals. In addition the results may explain the reported reduction of imaging quality and high uptake of radioactivity in the spleen of patients having repeated injections of mouse MAbs due to compled formation after development of human anti-mouse antibodies.
AU  - Senekowitsch, R.
AU  - Bode, W.
AU  - Reidel, G.
AU  - Glässner, H.
AU  - Möllenstädt, S.
AU  - Kriegel, H.
AU  - Pabst, H.W.
C1  - 41253
C2  - 40337
SP  - 13-19
TI  - Improved radioimmunoscintigraphy of human mammary carcinoma xenografts after injection of anti-antibody.
JO  - Nuklearmedizin
VL  - 26
IS  - 1
PY  - 1987
SN  - 0029-5566
ER  - 

TY  - JOUR
AU  - Senekowitsch, R.
AU  - Kriegel, H.
AU  - Pabst, H.W.
C1  - 41037
C2  - 0
SP  - 872-875
TI  - Der Einfluss einer Chemotherapie auf die Verteilung von Radiopharmazeutika im Osteoarkom der Maus; Möglichkeit einer Effektivitatskontrolle.
JO  - Nuklearmedizin
VL  - 20
IS  - Suppl.18
PY  - 1981
SN  - 0029-5566
ER  -